Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.

Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

Abstract: A distributed navigation system architecture includes a plurality of navigation platforms, each having a universal navigation processor configured to communicate with other universal navigation processors, one or more relative navigation systems configured to provide source information to the navigation platforms, an anchor navigation node disposed on one or more of the plurality of navigation platforms in order to form one or more anchor navigation platforms, the anchor navigation node, including an inertial navigation system, a clock, and one or more absolute navigation systems, configured to determine navigation information based on the inertial navigation system, the clock, the one or more absolute navigation systems and optionally the source information, the one or more anchor navigation platforms providing the navigation information to the other navigation platforms, and a navigation processor system in communication with each of the universal navigation processors in order to provide operating informat

Abstract: Systems, devices, and methods are described for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions, including autism spectrum disorders (ASD) by analysis of eye tracking data generated from feedback received as a result of display of specific predetermined visual stimuli to a subject or patient. Subsequent to a calibration phase, a testing procedure is performed by presenting predetermined stimuli (e.g., videos) to a subject via a display device. Eye tracking data (from the subject moving his or her eyes in response to predetermined movies or other visual stimuli) are collected. During the data collection period, the system periodically presents targets to reflexively elicit the subject's gaze. These data are used to later verify accuracy. Analysis of the subject's viewing patterns during these stimuli is used for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions such as ASD.

Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.

Abstract: Systems, devices, and methods are described for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions, including autism spectrum disorders (ASD) by analysis of eye tracking data generated from feedback received as a result of display of specific predetermined visual stimuli to a subject or patient. Subsequent to a calibration phase, a testing procedure is performed by presenting predetermined stimuli (e.g., videos) to a subject via a display device. Eye tracking data (from the subject moving his or her eyes in response to predetermined movies or other visual stimuli) are collected. During the data collection period, the system periodically presents targets to reflexively elicit the subject's gaze. These data are used to later verify accuracy. Analysis of the subject's viewing patterns during these stimuli is used for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions such as ASD.

Abstract: A ballistic curtain system includes a curtain having cells configured to stop a high-speed projectile and a motor connected to the curtain. The motor is capable of deploying or retracting the curtain.

Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage medium for implementing the advertisement of device status information. In one aspect, configuration data for the second device is obtained, where the configuration data indicating a current operating mode of the second device or a user-specified configuration of the second device. The stored radio transmitter identifier is accessed from the one or more data storage devices. A first advertisement that indicates the radio transmitter address and the radio transmitter identifier is generated. A second advertisement is generated that indicates the radio transmitter address and an encoding of the configuration data for the second device. Using the radio transmitter, a series of advertisements that includes at least the first advertisement and the second advertisement is broadcasted.

Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs.

Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.

Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

Abstract: Systems, devices, and methods are described for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions, including autism spectrum disorders (ASD) by analysis of eye tracking data generated from feedback received as a result of display of specific predetermined visual stimuli to a subject or patient. Subsequent to a calibration phase, a testing procedure is performed by presenting predetermined stimuli (e.g., videos) to a subject via a display device. Eye tracking data (from the subject moving his or her eyes in response to predetermined movies or other visual stimuli) are collected. During the data collection period, the system periodically presents targets to reflexively elicit the subject's gaze. These data are used to later verify accuracy. Analysis of the subject's viewing patterns during these stimuli is used for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions such as ASD.

Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

Abstract: The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof.

Abstract: The present invention relates to Polycomb Repressive Complex 2 (PRC2) peptide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant PRC2 methyltransferase activity.

Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Abstract: The combination of a power toothbrush and a charging system includes a charging base unit (12) having a charging coil (22) wound around the interior surface (20) of a portion of the charging base unit, and connectable to a source of electric power and a rinsing vessel (26) adapted to hold a toothbrush, the rinsing glass having a lower surface (27) configured to fit onto the upper surface (14) of the charging unit. The vessel is configured to hold a toothbrush in such a manner to prevent the toothbrush from tipping over when placed in the vessel, and further configured relative to the base unit that charging of the power toothbrush can occur between a pickup coil (46) in the handle of the toothbrush and the charging coil in the base charging unit.